

Stefania Landolfi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2902450/publications.pdf>

Version: 2024-02-01

66
papers

4,531
citations

201674

27
h-index

155660

55
g-index

69
all docs

69
docs citations

69
times ranked

8824
citing authors

#	ARTICLE	IF	CITATIONS
1	Analysis of <i>Fusobacterium</i> persistence and antibiotic response in colorectal cancer. <i>Science</i> , 2017, 358, 1443-1448.	12.6	983
2	Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to <i>BRAF</i> Mutation and Mismatch Repair Status of the MOSAIC Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 4176-4187.	1.6	515
3	Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. <i>Oncogene</i> , 2009, 28, 803-814.	5.9	385
4	β -catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. <i>Nature Medicine</i> , 2012, 18, 892-901.	30.7	336
5	Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2002, 440, 461-475.	2.8	287
6	Poorly differentiated carcinomas of the thyroid with trabecular, insular, and solid patterns. <i>Cancer</i> , 2004, 100, 950-957.	4.1	198
7	Level of <i>HER2</i> Gene Amplification Predicts Response and Overall Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab. <i>Journal of Clinical Oncology</i> , 2013, 31, 4445-4452.	1.6	170
8	p16 Overexpression Identifies HPV-positive Vulvar Squamous Cell Carcinomas. <i>American Journal of Surgical Pathology</i> , 2006, 30, 1347-1356.	3.7	150
9	Tankyrase Inhibition Blocks Wnt/ β -Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 644-656.	7.0	143
10	European guidelines on microscopic colitis: United European Gastroenterology and European Microscopic Colitis Group statements and recommendations. <i>United European Gastroenterology Journal</i> , 2021, 9, 13-37.	3.8	122
11	RHOA inactivation enhances Wnt signalling and promotes colorectal cancer. <i>Nature Communications</i> , 2014, 5, 5458.	12.8	95
12	A Personalized Preclinical Model to Evaluate the Metastatic Potential of Patient-Derived Colon Cancer Initiating Cells. <i>Clinical Cancer Research</i> , 2013, 19, 6787-6801.	7.0	80
13	TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence. <i>Journal of Clinical Investigation</i> , 2018, 128, 3887-3905.	8.2	79
14	Molecular Profiling of Patients with Colorectal Cancer and Matched Targeted Therapy in Phase I Clinical Trials. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2062-2071.	4.1	77
15	SPROUTY-2 and E-cadherin regulate reciprocally and dictate colon cancer cell tumorigenicity. <i>Oncogene</i> , 2010, 29, 4800-4813.	5.9	63
16	<i>DPYD</i> Genotyping to Predict Adverse Events Following Treatment With Fluorouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer. <i>JAMA Oncology</i> , 2016, 2, 655.	7.1	62
17	Brush border Myosin Ia has tumor suppressor activity in the intestine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 1530-1535.	7.1	60
18	The Receptor Tyrosine Kinase EPHB4 Has Tumor Suppressor Activities in Intestinal Tumorigenesis. <i>Cancer Research</i> , 2009, 69, 7430-7438.	0.9	58

#	ARTICLE	IF	CITATIONS
19	Myo5b knockout mice as a model of microvillus inclusion disease. <i>Scientific Reports</i> , 2015, 5, 12312.	3.3	52
20	p16INK4a Immunostaining Identifies Occult CIN Lesions in HPV-positive Women. <i>International Journal of Gynecological Pathology</i> , 2009, 28, 90-97.	1.4	48
21	Epigenetic Homogeneity Within Colorectal Tumors Predicts Shorter Relapse-Free and Overall Survival Times for Patients With Locoregional Cancer. <i>Gastroenterology</i> , 2016, 151, 961-972.	1.3	41
22	Risk of progression to high-grade anal intraepithelial neoplasia in HIV-infected MSM. <i>Aids</i> , 2015, 29, 695-702.	2.2	40
23	Risk factors for positive findings in patients with high-grade T1 bladder cancer treated with transurethral resection of bladder tumour (TUR) and bacille Calmette-Guérin therapy and the decision for a repeat TUR. <i>BJU International</i> , 2010, 105, 202-207.	2.5	36
24	Aprataxin Tumor Levels Predict Response of Colorectal Cancer Patients to Irinotecan-based Treatment. <i>Clinical Cancer Research</i> , 2010, 16, 2375-2382.	7.0	35
25	The effectiveness of electrocautery ablation for the treatment of high-grade anal intraepithelial neoplasia in HIV-infected men who have sex with men. <i>HIV Medicine</i> , 2016, 17, 524-531.	2.2	33
26	Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors. <i>BMC Cancer</i> , 2020, 20, 99.	2.6	31
27	Epigenetic EGFR Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas. <i>Clinical Cancer Research</i> , 2020, 26, 902-909.	7.0	29
28	The role of oncogenic human papillomavirus determination for diagnosis of high-grade anal intraepithelial neoplasia in HIV-infected MSM. <i>Aids</i> , 2017, 31, 2227-2233.	2.2	27
29	SPROUTY2 is a β -catenin and FOXO3a target gene indicative of poor prognosis in colon cancer. <i>Oncogene</i> , 2014, 33, 1975-1985.	5.9	26
30	Analysis of mutant allele fractions in driver genes in colorectal cancer – biological and clinical insights. <i>Molecular Oncology</i> , 2017, 11, 1263-1272.	4.6	26
31	Loss of the EPH receptor B6 contributes to colorectal cancer metastasis. <i>Scientific Reports</i> , 2017, 7, 43702.	3.3	25
32	Cyclin E amplification/overexpression is associated with poor prognosis in gastric cancer. <i>Annals of Oncology</i> , 2015, 26, 438-439.	1.2	23
33	Brush border myosin Ia inactivation in gastric but not endometrial tumors. <i>International Journal of Cancer</i> , 2013, 132, 1790-1799.	5.1	21
34	Mucosal microbial load in Crohn's disease: A potential predictor of response to faecal microbiota transplantation. <i>EBioMedicine</i> , 2020, 51, 102611.	6.1	21
35	Towards a new paradigm of microscopic colitis: Incomplete and variant forms. <i>World Journal of Gastroenterology</i> , 2016, 22, 8459.	3.3	19
36	Risk factors of high-grade anal intraepithelial neoplasia recurrence in HIV-infected MSM. <i>Aids</i> , 2017, 31, 1245-1252.	2.2	15

#	ARTICLE	IF	CITATIONS
37	Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer. <i>Scientific Reports</i> , 2019, 9, 13568.	3.3	14
38	Pre-operative chemoradiotherapy with UFT and Leucovorin in patients with advanced rectal cancer: A phase II study. <i>Radiotherapy and Oncology</i> , 2008, 89, 263-269.	0.6	13
39	Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. <i>Clinical and Translational Oncology</i> , 2015, 17, 264-273.	2.4	11
40	Topographical distribution of microscopic colitis and the importance of orientation of paraffin-embedded biopsies. <i>Human Pathology</i> , 2020, 103, 63-71.	2.0	11
41	Treatment outcomes of advanced digestive well-differentiated grade 3 NETs. <i>Endocrine-Related Cancer</i> , 2021, 28, 549-561.	3.1	10
42	Breast-Conservative Surgery Followed by Radiofrequency Ablation of Margins Decreases the Need for a Second Surgical Procedure for Close or Positive Margins. <i>Clinical Breast Cancer</i> , 2014, 14, 346-351.	2.4	9
43	Investigation of the role of tyrosine kinase receptor EPHA3 in colorectal cancer. <i>Scientific Reports</i> , 2017, 7, 41576.	3.3	9
44	Brief Report: Effectiveness of Trichloroacetic Acid vs. Electrocautery Ablation for the Treatment of Anal High-Grade Squamous Intraepithelial Lesion in HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, 612-616.	2.1	8
45	Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib. <i>Oncologist</i> , 2019, 24, 680-687.	3.7	7
46	Recomendaciones para la determinación de mutaciones de K-RAS en cáncer de colon. <i>Revista Espanola De Patologia</i> , 2012, 45, 76-85.	0.2	6
47	Detailed characterization of <i>MLH1</i> p. <i>D41H</i> and p. <i>N710D</i> variants coexisting in a Lynch syndrome family with conserved <i>MLH1</i> expression tumors. <i>Clinical Genetics</i> , 2015, 87, 543-548.	2.0	6
48	Gastrointestinal endarteropathy in adult dermatomyositis. <i>Joint Bone Spine</i> , 2016, 83, 353-354.	1.6	3
49	miRNA landscape in primary tumors and matched metastases in gastrointestinal stromal tumors. <i>Epigenomics</i> , 2021, 13, 369-377.	2.1	2
50	Quantifying intraepithelial lymphocytes and subepithelial collagen band in microscopic colitis, extracting insights into the interrelationship of lymphocytic and collagenous colitis. <i>Annals of Diagnostic Pathology</i> , 2021, 52, 151741.	1.3	2
51	Prognostic impact of primary tumor site location in metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 578-578.	1.6	2
52	Actualización de la recomendación para la determinación de biomarcadores en el carcinoma colorrectal. Consenso Nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica. <i>Revista Espanola De Patologia</i> , 2015, 48, 14-24.	0.2	1
53	Young-onset colorectal cancer: A call for action.. <i>Journal of Clinical Oncology</i> , 2021, 39, 10563-10563.	1.6	1
54	Outcome evolution of matched molecular targeted agents (MTAs) in metastatic colorectal cancer (CRC) patients (pts): VHIO experience.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3602-3602.	1.6	1

#	ARTICLE	IF	CITATIONS
55	Survival determinants with matched targeted therapies in BRAF mutant metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2016, 34, 649-649.	1.6	1
56	Tumor trofoblástico epitelioide de presentaci3n en la posmenopausia. Progresos En Obstetricia Y Ginecologia, 2007, 50, 116-120.	0.0	0
57	Methodological approach to Microscopic Colitis diagnosis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 621-622.	2.8	0
58	Acquired hepatocerebral degeneration in a metastatic neuroendocrine tumor long-term survivor "an update on neuroendocrine neoplasms treatment: A case report. World Journal of Hepatology, 2021, 13, 611-619.	2.0	0
59	Senescence, a new concept in pathologic response evaluation of rectal carcinomas (RC) after neoadjuvant treatment.. Journal of Clinical Oncology, 2012, 30, e21021-e21021.	1.6	0
60	Molecular characterization of nonpancreatic neuroendocrine neoplasms (NENS): First description of mutations in the tumor suppressor gene (TSG) SMARCB1 in NENS of colorectal origin using next-generation sequencing (NGS).. Journal of Clinical Oncology, 2013, 31, 4135-4135.	1.6	0
61	Coexisting KRAS and PIK3CA exon 20 mutations as a potential poor-prognosis factor in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2014, 32, 3591-3591.	1.6	0
62	Clinical and molecular characterization of refractory BRAF mutant metastatic colorectal carcinoma (mCRC): Vall Hebron Institute of Oncology phase I program cohort.. Journal of Clinical Oncology, 2015, 33, 587-587.	1.6	0
63	DYPD genotyping to predict toxicity in patients with stage III colon cancer treated with 5-fluorouracil-based adjuvant chemotherapy in the PETACC-8 phase III trial.. Journal of Clinical Oncology, 2015, 33, 3584-3584.	1.6	0
64	Knocking on molecular alterations in advanced gastric cancer (AGC).. Journal of Clinical Oncology, 2015, 33, 4063-4063.	1.6	0
65	Clonality patterns of driver mutations (mut) to reveal spatial-temporal genomic heterogeneity in colorectal cancer (CRC).. Journal of Clinical Oncology, 2016, 34, 3509-3509.	1.6	0
66	Translating molecular subtypes of gastric and gastroesophageal junction cancer (GC and GEJC) to the metastatic (met) setting: Prevalence and outcome data. Translating molecular subtypes of gastric and gastroesophageal junction cancer (GC and GEJC) to the metastatic (met) setting: prevalence and outcome data.. Journal of Clinical Oncology, 2018, 36, 4071-4071.	1.6	0